{"DataElement":{"publicId":"2950646","version":"1","preferredName":"Interruption Or Modification Agent Name","preferredDefinition":"The name of the agent that had an interruption or modification in a given period.","longName":"INTR_MOD_AGT_NM","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"2950644","version":"1","preferredName":"Agent Interruption Or Modification","preferredDefinition":"Information pertaining to the interruption; a time interval during which there is a temporary cessation of something or modification; the act of making something different of an active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"AGT_INTR_MOD","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2223333","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B10F2-76A7-2830-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2950642","version":"1","preferredName":"Interruption Or Modification","preferredDefinition":"Interruption; a time interval during which there is a temporary cessation of something.:Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Modification; the act of making something different.","longName":"C25542:C37998:C25572","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interruption","conceptCode":"C25542","definition":"A time interval during which there is a temporary cessation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Modification","conceptCode":"C25572","definition":"Modification; the act of making something different.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753351DE-4B7F-B5B5-E040-BB89AD434EA9","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"ONEDATA","dateModified":"2009-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"753351DE-4B90-B5B5-E040-BB89AD434EA9","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2950602","version":"1","preferredName":"Agent Assignment Name","preferredDefinition":"The name of the appointed agent.","longName":"AGT_ASSIGN_NM","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Celecoxib","valueDescription":"Celecoxib","ValueMeaning":{"publicId":"2577801","version":"1","preferredName":"Celecoxib","longName":"2577801","preferredDefinition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Celecoxib","conceptCode":"C1728","definition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7531E665-39A7-B791-E040-BB89AD432F47","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"ONEDATA","dateModified":"2009-10-05","deletedIndicator":"No"},{"value":"Zileuton and Celecoxib","valueDescription":"Zileuton And Celecoxib","ValueMeaning":{"publicId":"2950604","version":"1","preferredName":"Zileuton And Celecoxib","longName":"2950604","preferredDefinition":"A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zileuton","conceptCode":"C26667","definition":"A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Celecoxib","conceptCode":"C1728","definition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7531E665-39B7-B791-E040-BB89AD432F47","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7531E665-39D0-B791-E040-BB89AD432F47","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"ONEDATA","dateModified":"2009-10-05","deletedIndicator":"No"},{"value":"Zileuton","valueDescription":"Zileuton","ValueMeaning":{"publicId":"2950661","version":"1","preferredName":"Zileuton","longName":"2950661","preferredDefinition":"A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zileuton","conceptCode":"C26667","definition":"A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75442F1B-EFC8-748B-E040-BB89AD431683","latestVersionIndicator":"Yes","beginDate":"2009-10-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75442F1B-EFE1-748B-E040-BB89AD431683","beginDate":"2009-10-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-06","modifiedBy":"ONEDATA","dateModified":"2009-10-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2950601","version":"1","preferredName":"Agent Assignment Name","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):Assignment; an undertaking that you have been assigned to do.:The words or language units by which a thing is known.","longName":"C1708:C25426:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7531E665-3982-B791-E040-BB89AD432F47","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"ONEDATA","dateModified":"2009-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7531E665-3993-B791-E040-BB89AD432F47","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"MAESKEB","dateModified":"2009-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2194255","version":"1","longName":"Type of Condition","context":"DCP","ClassificationSchemeItems":[{"publicId":"2936518","version":"1","longName":"Polyphenon E in Women w/ Modulation of Arachidonic Acid","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Agent","type":"Preferred Question Text","description":"Agent","url":null,"context":"DCP"}],"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"753351DE-4BA8-B5B5-E040-BB89AD434EA9","latestVersionIndicator":"Yes","beginDate":"2009-10-05","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-05","modifiedBy":"MAESKEB","dateModified":"2009-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}